Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma
This trial will determine the feasibility and efficacy of lenalidomide as maintenance therapy in Multiple Myeloma patients treated with dose intensive chemotherapy (Melphalan 200 mg/m2) with autologous PBSC transplant.
Multiple Myeloma
DRUG: Melphalan|DRUG: Lenalidomide
Event Free Survival, Duration of time until patient experiences an event (recurrence, relapse or death), 3 years
Disease Response, Number of patients that have complete and very good partial responses., 2 years|Overall survival, Duration of time from Day 0 until death., 4 years|Grade > 2 toxicities, Percent of patients experiencing one or more toxicity greater than 2., 4 years|Incidence of infections, Percent of patients experiencing a definite or probable viral, fungal or bacterial infection., 4 years|Treatment related Mortality, Number of patients that experience a death from causes other relapse or progression., 4 years
This trial will determine the feasibility and efficacy of lenalidomide as maintenance therapy in Multiple Myeloma patients treated with dose intensive chemotherapy (Melphalan 200 mg/m2) with autologous PBSC transplant.